Last updated on July 2017

A Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients


Brief description of study

This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients

Clinical Study Identifier: NCT02724254

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Eric Wenzel

Anaconda Invesigational Site
Buenos Aires, Argentina
  Connect »

Eric Wenzel

Anaconda Investigational Site
Buenos Aires, Argentina
  Connect »

Eric Wenzel

Anaconda Investigational Site
Cordoba, Argentina
  Connect »

Eric Wenzel

Anaconda Investigational Site
Córdoba, Argentina
  Connect »

Eric Wenzel

Anaconda Investigational Site
Mendoza, Argentina
  Connect »

Eric Wenzel

Anaconda Investigational Site
Sante Fe, Argentina
  Connect »

Eric Wenzel

Anaconda Investigational Site
Concepción, Chile
  Connect »

Eric Wenzel

Anaconda Investigational Site
Santiago, Chile
  Connect »

Eric Wenzel

Anaconda Investigational Site
Cumbaya, Ecuador
  Connect »

Eric Wenzel

Anaconda Investigational Site
Guayaquil, Ecuador
  Connect »

Eric Wenzel

Anaconda Investigational Site
Quito, Ecuador
  Connect »

Eric Wenzel

Anaconda Investigational Site
Belgrade, Serbia
  Connect »

Eric Wenzel

Anaconda Investigational Site
Novi Sad, Serbia
  Connect »